Showing results (91-100 of 402) with videos related to

Sort By:
Pageof 41
Journal of Experimental & Clinical Cancer Research : CR|May 10, 2011
Maintenance therapy in NSCLC: why? To whom? Which agent?Silvia Novello, Michele Milella, Marcello Tiseo, et al.
Journal of Translational Medicine|April 25, 2019
Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracyMatteo Pallocca, Davide Angeli, Fabio Palombo, et al.
Cancer|November 28, 2007
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trialsFederica Cuppone, Emilio Bria, Sunil Verma, et al.
International Journal of Molecular Sciences|March 28, 2026
Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging EntityIlaria Mariangela Scaglione, Adele Bonato, Alessandra Dodi, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|April 5, 2022
Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy?Sara Pilotto, Francesco Agustoni, Anna Maria Morelli, et al.
Clinical Pharmacokinetics|March 11, 2009
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic functionAlessandra Felici, Susanna Di Segni, Michele Milella, et al.
The Oncologist|March 13, 2020
Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?Alice Avancini, Giulia Sartori, Anastasios Gkountakos, et al.
Frontiers in Oncology|June 20, 2022
Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR InhibitionFabiana Conciatori, Erica Salvati, Ludovica Ciuffreda, et al.
International Journal of Molecular Sciences|December 3, 2020
Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision OncologyChiara Bazzichetto, Claudio Luchini, Fabiana Conciatori, et al.
Clinical Lung Cancer|September 2, 2021
Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy InductionLorenzo Belluomini, Valeria Dionisi, Silvia Palmerio, et al.
Pageof 41